These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23782513)

  • 1. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
    Solomón MT; Selva JC; Figueredo J; Vaquer J; Toledo C; Quintanal N; Salva S; Domíngez R; Alert J; Marinello JJ; Catalá M; Griego MG; Martell JA; Luaces PL; Ballesteros J; de-Castro N; Bach F; Crombet T
    BMC Cancer; 2013 Jun; 13():299. PubMed ID: 23782513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.
    Solomon MT; Miranda N; Jorrín E; Chon I; Marinello JJ; Alert J; Lorenzo-Luaces P; Crombet T
    Cancer Biol Ther; 2014 May; 15(5):504-9. PubMed ID: 24521695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience.
    Cabanas R; Saurez G; Rios M; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Avila M; Herrera R; Infante M; Echevarria E; Moreno M; Luaces PL; Ramos TC
    MAbs; 2013; 5(2):202-7. PubMed ID: 23575267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility.
    Cabanas R; Saurez G; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Valle L; Infante M; Avila M; Herrera R; Hechavarria E; Rios M; Fernández A; Lorenzo Luaces P; Crombet Ramos T
    Cancer Biother Radiopharm; 2014 May; 29(4):173-8. PubMed ID: 24784755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
    Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
    Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
    Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
    Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
    Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
    J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study.
    Fleischhack G; Massimino M; Warmuth-Metz M; Khuhlaeva E; Janssen G; Graf N; Rutkowski S; Beilken A; Schmid I; Biassoni V; Gorelishev SK; Kramm C; Reinhard H; Schlegel PG; Kortmann RD; Reuter D; Bach F; Iznaga-Escobar NE; Bode U
    J Neurooncol; 2019 May; 143(1):107-113. PubMed ID: 30830679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
    Yang QY; Shen D; Sai K; Mu YG; Jiang XB; Zhang XH; Chen ZP
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):232-5. PubMed ID: 21575527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.
    Rodríguez MO; Rivero TC; del Castillo Bahi R; Muchuli CR; Bilbao MA; Vinageras EN; Alert J; Galainena JJ; Rodríguez E; Gracias E; Mulén B; Wilkinson B; de Armas EL; Pérez K; Pineda I; Frómeta M; Leonard I; Mullens V; Viada C; Luaces P; Torres O; Iznaga N; Crombet T
    Cancer Biol Ther; 2010 Mar; 9(5):343-9. PubMed ID: 20448462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.
    Massimino M; Biassoni V; Miceli R; Schiavello E; Warmuth-Metz M; Modena P; Casanova M; Pecori E; Giangaspero F; Antonelli M; Buttarelli FR; Potepan P; Pollo B; Nunziata R; Spreafico F; Podda M; Anichini A; Clerici CA; Sardi I; De Cecco L; Bode U; Bach F; Gandola L
    J Neurooncol; 2014 Jun; 118(2):305-312. PubMed ID: 24696052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
    Ramos TC; Figueredo J; Catala M; González S; Selva JC; Cruz TM; Toledo C; Silva S; Pestano Y; Ramos M; Leonard I; Torres O; Marinello P; Pérez R; Lage A
    Cancer Biol Ther; 2006 Apr; 5(4):375-9. PubMed ID: 16575203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
    Narita Y; Muragaki Y; Kagawa N; Asai K; Nagane M; Matsuda M; Ueki K; Kuroda J; Date I; Kobayashi H; Kumabe T; Beppu T; Kanamori M; Kasai S; Nishimura Y; Xiong H; Ocampo C; Yamada M; Mishima K
    Cancer Sci; 2021 Dec; 112(12):5020-5033. PubMed ID: 34609773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.
    Kato K; Ura T; Koizumi W; Iwasa S; Katada C; Azuma M; Ishikura S; Nakao Y; Onuma H; Muro K
    Cancer Sci; 2018 Mar; 109(3):785-793. PubMed ID: 29285832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.
    You B; Brade A; Magalhaes JM; Siu LL; Oza A; Lovell S; Wang L; Hedley DW; Nicacio LV; Chen EX
    Invest New Drugs; 2011 Oct; 29(5):996-1003. PubMed ID: 20454832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
    Cetina L; Crombet T; Jiménez-Lima R; Zapata S; Ramos M; Avila S; Coronel J; Charco E; Bojalil R; Astudillo H; Bazán B; Dueñas-González A
    Cancer Biol Ther; 2015; 16(5):684-9. PubMed ID: 25802932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.
    Okamoto W; Yoshino T; Takahashi T; Okamoto I; Ueda S; Tsuya A; Boku N; Nishio K; Fukuoka M; Yamamoto N; Nakagawa K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1063-71. PubMed ID: 24046058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.